New immunotherapy combo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of immunotherapy drugs (AK129 and cadonilimab) plus chemotherapy for people with advanced stomach or GEJ cancer who have not had treatment before. The goal is to see if adding these immunotherapies helps shrink tumors or slow cancer growth better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus (GEJ).
- Your cancer is advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have not received any chemotherapy or immunotherapy for advanced cancer yet.
- You have at least one tumor that can be measured on a CT scan or MRI.
- Your cancer is not HER2 positive (a specific protein marker).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This study tests a combination of two experimental drugs (QLS31905 and QL2107) plus chemotherapy (oxaliplatin and capecitabine) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors and control the cancer better than standard care.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.